The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse An Open-label, phase I rising multiple dose, single-centre study to determine the PK & tolerabilityof ZD6474 at different dose levels in Chinese patients with solid malignancy tumor.
- collapse A Phase I, open label study to assess the saftey and tolerability of ZD6474 (ZACTIMA) in combination with Vinorelbine (Navelbine) or Gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.
- collapse A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.
- collapse A Randomised, Double-blind, Parallel-group, Dose Finding Study to assess the Efficacy and Safety of ZD6474 in patients with advanced, metastatic, or recurrent NSCLC who have failed previous chemotherapy regimens, at least one of which contained platinum.
- collapse A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
- collapse Main
- collapse A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxe l(Taxotere) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) after Failure of Prior Platinum-based Chemotherapy
- collapse (NCIC CTG) A phase two study of ZD6474 in patients with relapsed multiple myeloma
- collapse Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
- collapse A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination with Liposomal Doxorubicin (Caelyx) in Patients with Advanced Solid Tumors
